What Is Canagliflozin At Lowering Blood Glucose Levels?

Diabetes can be treated in three basic ways: by diet, by diet in conjunction with tablets, or diet in conjunction with insulin. Diet serves as an initial control for non-urgent patients. If a person’s diet will have a major effect on glycaemic control, it does so reasonably quickly, within a few weeks of changing

Everybody knows that obesity is a big factor in developing type-2 diabetes, and that part of coping with this metabolic disorder is lifestyle change. If blood glucose does not go down, then medicines are introduced. Some type-2 diabetics even have to administer insulin in order to keep their blood glucose levels

Incretin based drugs have proven to be effective glucose-lowering agents (Butler et al, 2013). But there have been concerns with respect to the long-term consequences of using such therapies. The issues raised were regarding their causal relationship with acute pancreatitis (AP). There are clearly conflicting evidence that have been presented in preclinical studies and in epidemiologic studies which suggest an association which may or may not be a causal relationship between these drugs and AP. (Butler et al, 2013)

Due to its insulin-independent mechanism of action that produces glucose excretion in the urine, dapagliflozin was known to be very effective when utilized as monotherapy, plus complementary and effective when used in combination with other anti-diabetic drugs; the clinical trial program was aimed to discover this therapeutic potential. Also, the program discovered the persistent calories loss in the

Canagliflozin is prescribed to patients with type 2 diabetes.1 The medication along with proper diet and frequent exercise will improve glycemic control in patients with type 2 diabetes.1 Canagliflozin is in the class of sodium-glucose cotransporter 2 (SGLT2) inhibitor.1,2 This medication reduces reabsorption of filtered glucose by lowering the threshold of glucose and increasing the amount of glucose that will be excreted.2

Rozenfeld et all 2008 in his article evaluated the adherence to oral hypoglycemic agents (OHAs) in diabetic patients. In his retrospective study, he conducted a research in a medical center where he found the relation between the glycosylated hemoglobin and adherence. In his study, 80% of the participants were adherent to the therapy showing inverse relationship with HbA1C level. As the level of adherence increases in patients the HbA1C would decrease below 7% proving its adherence. Most of the patients were using metformin (46%). According to him, if the efforts would done to pay attention to each patient than adherence and glycemic control could be increased and it would move towards the better health of the patient .

Metformin is widely used to treat type 2 diabetes who do not have severe nephritis, cardiovascular disease or liver disease. It is one of the best first line treatment for type 2 diabetes which was first marketed named as Glucophage. Metformin also used in the treatment of polycystic ovary syndrome and increasing the use day by day.

There is growing concern that intense glucose lowering or the use of certain agents may be associated with adverse cardiovascular outcomes.

Diabetes mellitus is a chronic disorder caused by insulin deficiency that may be partial or complete, resulting in hyperglycaemia leading to acute and chronic difficulty. The frequency of diabetes mellitus is on rise all over the world. The dominance of diabetes has and will continue to have burden on health and finances of economic climates, which in turn, will put impact on persons, families, and nations.(food research international, vol.44(4):862-867) Control of plasma glucose concentrations is essential to reduce the incidence and brutality of long term diabetes effect. Synthetic drugs are likely to give serious effects in addition they are not suitable for eating during situation like pregnancy. Apart from conventional diabetes

Materials and Methods: A systematic clinical case study was performed to note an audit of type 2 diabetes patients initiated on invokana and forixga along with their concomitant medication in a diabetes specialist outpatient

The treatment of diabetes is dependent on its type and its severity, insulin, exercise, and a diabetic diet is used to treat type 1 diabetes, whiles type 2 diabetes is initially controlled with weight loss, type 2 diabetic diet and physical activity; when these initiatives fail to balance elevated blood sugars, oral medications are prescribed and if that proves few futile then insulin and multiple injectable medications are introduced (Medicinenet2). One cannot prevent type 1 diabetes; however, one can prevent type 2 diabetes by sustaining a balanced weight and engaging in regular physical activity (Medicinenet2). I will conduct an investigation to determine whether Insulin used in the

Pharmacological interventions used to improve glucose control include both oral glucose lowering agents and injectables including glucose like peptide & insulin. Apart from insulin the choice of available pharmacological interventions to treat diabetics has expanded rapidly over the past decade. Till date, the efficacy & safety of these therapies have not been well documented in people with diabetics & CKD.

Diabetic patients have a major risk of cardiovascular disease leading cause of life threatening and death. The goal of this study is to select drugs that do not increase cardiovascular risk. The US FDA has recommended in its Guidance for Industry for drug developers in year 2008, that type 2 diabetes new drugs for clinical trials should fulfill gycemic benefit and cardiovascular safety, and rule out potentially harmful drug interactions. The European Medicines Agency recommended same. Cautious selection of the drug therapy, specifically cardiovascular safety with controlled diabetes. Patients with diabetes often showing atherosclerosis and are at high risk of morbidity and mortality from cardiovascular disease (CVD). Patients with diabetes have twice threat for stroke, heart related disease, and death from heart disease compared to non diabetic patients. Statics of 2010 showed that 1.9 million people aged 22 years or above in the US were identified with diabetes. Metformin is first choice of the treatment for type 2 diabetes mellitus due to its very effective glucose lowering formula, used from last many years, cheap, no effect on weight, causes least hypoglycemia, taken orally, and has the possible to decrease CV harm. Saxagliptin is basically a Dipeptidyl peptidase 4 (DPP-4) enzyme that reduced 0.6%-0.9% HgA1c by increasing body’s sugar utilization, prevent atherosclerosis and myocardial damage, improving lipid profile and endothelial dysfunction, and lower the blood

Oral anti diabetic agents are used as pharmacotherapy options mainly for type 2 diabetes patients or as an adjuvant therapy for type 1 diabetes patients, who need an oral agent along with insulin/insulin analogues for better glycemic control. There are a wide variety of oral anti diabetic drug classes that are available. The choice of pharmacotherapy is patient specific and usually a stepped therapy approach is applied and titrated as per individual patient requirements. The article here is a detailed overview of the different classes of these oral agents, their pharmacology, comparative efficacy, efficacy results from clinical trials, general recommendations etc.

Despite the flaws in the design of this short-term trial, are the results helpful in determining whether practitioners should choose this adjunctive therapy — should it be approved? If, as in the trial, sotagliflozin were added to insulin therapy, the proportion of patients who would achieve a glycated hemoglobin level of less than 7% with no episodes of ketoacidosis or severe hypoglycemia would be increased by 13 percentage points (with less than one third of the patients treated with sotagliflozin achieving the target glycated hemoglobin level) and the glycated hemoglobin level would be 0.46 percentage points (6%) below the level among those who receive insulin alone.